

Chisomicines A–C, Limonoids from *Chisocheton ceramicus*

Ibrahim A. Najmuldeen,[†] A. Hamid A. Hadi,^{*,†} Khalijah Awang,[†] Khalit Mohamad,[‡] Kamal Aziz Ketuly,[§] Mat Ropi Mukhtar,[†] Soon-Lim Chong,[†] Gomathi Chan,[†] Mohd Azlan Nafiah,[⊥] Ng Seik Weng,[†] Osamu Shirota,^{||} Takahiro Hosoya,[▽] Alfarius E. Nugroho,[▽] and Hiroshi Morita^{*,▽}

[†]Department of Chemistry, Faculty of Science, University of Malaya, 50603 Kuala Lumpur, Malaysia

[‡]Department of Pharmacy, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia

[§]Department of Chemistry, Faculty of Science, University of Malaya, 50603 Kuala Lumpur, Malaysia


[⊥]Department of Chemistry, Faculty of Science and Mathematics, University Pendidikan Sultan Idris, 35900 Tanjung Malim, Perak, Malaysia

^{||}Faculty of Pharmaceutical Sciences at Kagawa Campus, Tokushima Bunri University, 1314-1 Shido, Sanuki City, Kagawa 769-2193, Japan

[▽]Faculty of Pharmaceutical Sciences, Hoshi University, Shinagawa, Tokyo 142-8501, Japan


S Supporting Information

ABSTRACT: Three new limonoids, chisomicines A–C (1–3), have been isolated from the bark of *Chisocheton ceramicus*. Their structures were determined by 2D NMR, CD spectroscopic methods, and X-ray analysis. Chisomicine A (1) exhibited NO production inhibitory activity in J774.1 cells stimulated by LPS dose-dependently at high cell viability.



Limonoids from Meliaceae plants have been the subject of various studies due to their antifeedant, insecticide, antitumor, and antimalarial activities.^{1,2} In addition, their diverse structures, with the oxidized backbone and the side chain moiety bonded to ring D in the intact tetranortriterpenoid nucleus, have attracted great interest.³

We have found that an alcoholic extract of *Chisocheton ceramicus* (Miq.) C. Dc. (Meliaceae) bark is a rich source of interesting limonoids, named as a series of ceramicines.⁴ In continuation of our research,⁵ we have isolated three new limonoids: an A2,B,D-*seco* type (1) named chisomicine A, a phragmalin type (2) named chisomicine B, and an A1,A2-*seco*-phragmalin type (3) named chisomicine C. Two known mexicanolide-type limonoids, 14-deoxyxylocensin K⁶ and proceranolide,⁷ were also isolated. We now wish to report the isolation and structure elucidation of compounds 1–3 and the NO production inhibitory activity of 1.



Chisomicine A (1) was obtained as white, amorphous powder, and the HRESIMS displayed a pseudomolecular ion peak at 573.2468 ($M + Na$)⁺ corresponding to the molecular formula

C₃₂H₃₈O₈. IR absorption at 1734 cm⁻¹ indicated the presence of a carbonyl group. The ¹³C NMR and DEPT spectra revealed 32 carbon resonances due to four carbonyls, four sp² quaternary carbons, three sp³ quaternary carbons, six sp² methines, four sp³ methines, five sp³ methylenes, and six methyls. Among them, two sp³ methines (δ_C 76.8 and 80.2), one sp³ methyl (δ_C 52.0), and two sp² methines (δ_C 141.7 and 142.8) were ascribed to those bearing an oxygen atom.

Five partial structures, a (C-2, C-3, and C-30), b (from C-5 to C-6), c (from C-9 to C-12), d (from C-22 to C-23), and e (from C-3' to C-4'), were deduced from ¹H–¹H COSY analysis of 1 in CDCl₃ (see Supporting Information). The presence of a bicyclo-[5.2.1]dec-3-en-8-one unit containing the partial structure a was supported by HMBC correlations. HMBC correlations for H-3, H-5, H₃-28, and H₂-29 of C-4 (δ_C 43.3) provided the connectivity of partial structures a and b through the C-4 atom. The presence of a cyclopentanone ring connected with the partial structure b was assigned by the HMBC correlations for H₂-29 of C-1 (δ_C 220.6), C-5 (δ_C 40.5), and C-10 (δ_C 54.2) and for H-5 of C-1 and C-10. Connection of partial structures a, b, and c was assigned based on HMBC correlations for H₃-19 of C-5, C-9 (δ_C 44.4), and C-10 and for H-9 of C-8 (δ_C 131.0) and C-10. The presence of a methoxy carbonyl group connected to the partial structure b was supported by the HMBC correlations for H₂-6 and H₃-OMe of C-7 (δ_C 174.1). Partial structure e constructing

Received: January 6, 2011

Published: March 23, 2011




Figure 1. X-ray crystallographic structure of **2**.

(*E*)-2-methylbut-2-enoic acid was attached at C-3 by the HMBC correlations for H-3 and H-3' of C-1' (δ_C 167.1). The presence of a β -furyl ring at C-17 was also assigned from the HMBC correlations. In addition, the HMBC correlations for H₃-18 of C-12 (δ_C 28.5), C-13 (δ_C 37.8), C-14 (δ_C 131.6), and C-17 (δ_C 80.2) and for H-15 of C-8, C-13, C-14, and C-16 (δ_C 169.2) indicated the presence of an isochromenone containing the partial structure **c** and a tetrahydropyran-2-one ring. Thus, chisomicine A (**1**) was concluded to be a unique limonoid possessing a bicyclo[5.2.1]dec-3-en-8-one ring system, an isochromenone, and a β -furyl ring at C-17.

NOESY correlations among H-2, H-3, and H-29b indicated that the ester at C-3 and Me-28 at C-4 took a β -orientation. Furthermore, the relative configurations at C-5, C-13, and C-17 were deduced from NOESY correlations among H-5, H-12a, and H-17. The relative configurations at C-9 and C-10 were assigned by NOESY correlations of H-9/H-30 and H₃-19 and of H-30/H₂-15.

Chisomicine B (**2**) was obtained as colorless needles (mp 176–178 °C), and the HRESIMS displayed a pseudomolecular ion peak at 569.2706 ($M + H$)⁺, corresponding to the molecular formula C₃₂H₄₀O₉. IR absorptions implied the presence of carbonyl (1735 and 1703 cm⁻¹) functionalities. The ¹³C NMR spectrum revealed 32 carbon resonances due to three carbonyls, two for an ester at δ_C 168.4 (C-1') and δ_C 173.8 (C-7) and one for a lactone at δ_C 169.4 (C-16), two sp² quaternary carbons, five sp³ quaternary carbons, four sp² methines, seven sp³ methines, five sp³ methylenes, and six methyls. Among them, two sp³ quaternary carbons (δ_C 80.0 and 61.3), three sp³ methines (δ_C 78.6, 77.6, and 59.6), one sp³ methyl (δ_C 52.0), and two sp² methines (δ_C 141.4 and 143.1) were ascribed to those bearing an oxygen atom.

Analysis of the 2D NMR data revealed a similar skeleton to that of **1** except for the connection between C-1 and C-2. The connection between C-1 and C-2 was suggested by the HMBC correlation of H-30 to C-1 (δ_C 80.0), and on the basis of the HRESIMS data and the ¹³C chemical shift of C-8 and C-30 (δ_C 61.3 and 59.6, respectively) **2** was assumed to have a C-8–C-30 epoxy ring. Thus the gross structure of **2** was suggested to possess a phragmalin-type skeleton with β -furan, δ -lactone, epoxy rings, and α -methyl crotonate moieties. The relative structure and the presence of the C-8–C-30 epoxy ring of **2** were confirmed by X-ray crystallography, as shown in Figure 1.

Chisomicine C (**3**) was isolated as a white, amorphous powder. The HRESIMS displayed a pseudomolecular ion peak at 607.2512 ($M + Na$)⁺ corresponding to the molecular formula




Figure 2. Experimental and calculated CD and UV spectra of **1**.

C₃₂H₄₀O₁₀. IR absorptions implied the presence of carbonyl functionalities (1732, 1718, and 1706 cm⁻¹).

On the basis of analysis of both 1D and 2D NMR data of **3**, the structure was deduced to be an oxidized-phragmalin-type limonoid with a rare C-1–C-29 oxygen bridge similar to granaxycarpin C.⁸ The C-8–C-30 double bond was confirmed by the ¹H–¹H COSY correlation of H-2/H30 and by the HMBC correlation of H-2/C-8. The relative structure of **3** was assumed to be similar to **2** and granaxycarpin C and was confirmed by the observed NOESY correlations. The α -orientation of an OH at C-14 was deduced by the NOESY correlations of H-5/H-17 and H-17/H-3'.

The absolute configuration of **1** was assigned by comparing the experimental CD spectrum with the calculated CD spectrum (CD calculations were performed by Turbomole 6.1⁹ using the RI-TD-DFT-BP86/aug-cc-pVDZ¹⁰ level of theory on RI-DFT-BP86/SVP¹⁰-optimized geometries). The calculated CD spectrum of the 3*R*, 4*R*, 5*S*, 9*S*, 10*R*, 13*R*, 17*R* isomer of **1** showed a CD pattern similar to that of the experimental spectrum (Figure 2). Therefore, the absolute configuration of **1** was proposed as shown in the structures.

A plausible biogenetic pathway for chisomicines A–C (**1–3**) would be that they could be derived from a mexicanolide skeleton (see Supporting Information). Chisomicine B (**2**), with a phragmalin skeleton, could be biosynthesized from the coupling of C-1–C-29 of a mexicanolide skeleton, and an oxidative cleavage of the C-1–C-2 bond in chisomicine B (**2**) followed by dehydroxylation would yield chisomicine A (**1**), whereas chisomicine C (**3**) could be biosynthesized from a mexicanolide skeleton after oxidation at C-29 followed by formation of a hemiketal linkage.

Chisomicine A (**1**) inhibited NO production in J774.1 cells dose dependently stimulated by LPS and also showed little effect on cell viability (Figure 3, IC₅₀ 20.2 μ M).¹¹ However, chisomicines B (**2**) and C (**3**), 14-deoxyxylocensin K, and proceranolide did not show NO production inhibitory activity.

EXPERIMENTAL SECTION

General Experimental Procedures. Optical rotations were measured on a JASCO DIP-1000 automatic digital polarimeter. UV spectra were obtained on an Ultrospec 2100 Pro spectrophotometer, and IR spectra were recorded on a JASCO FT/IR-4100 spectrophotometer. High-resolution ESIMS were obtained on a LTQ Orbitrap XL (Thermo Scientific). ¹H and 2D NMR spectra were recorded on Bruker AV700 and JEOL ECA400 spectrometers, and chemical shifts were referenced to the residual solvent peaks (δ_H 7.26 and δ_C 77.0 for chloroform-*d*). Standard pulse sequences were employed for the 2D NMR experiments. ¹H–¹H COSY, HOHAHA,

and NOESY spectra were measured with spectral widths of both dimensions of 4800 Hz, and 32 scans with two dummy scans were accumulated into 1K data points for each of 256 t_1 increments. NOESY spectra in the phase-sensitive mode were measured with a mixing time of 800 ms. For HMQC spectra in the phase-sensitive mode and HMBC spectra, a total of 256 increments of 1K data points were collected. For HMBC spectra with Z-axis PFG, a 50 ms delay time was used for long-range C—H coupling. Zero-filling to 1K for F_1 and multiplication with squared cosine-bell windows shifted in both dimensions were performed prior to 2D Fourier transformation.

Material. The bark of *C. ceramicus* was collected in 2000 from Hutan Simpan Bukit Enggang, Malaysia. The plant species was identified by Mr. Teo Leong Eng, with a voucher specimen (No. KL 4973), and the herbarium specimen was deposited in the herbarium of the Chemistry Department, University of Malaya.

Extraction and Isolation. The dried and powdered bark of *C. ceramicus* (900 g) was extracted successively with MeOH, and the MeOH extract (200 g) was partitioned with 10% MeOH(aq) and EtOAc. EtOAc-soluble materials (10 g) were subjected to a silica gel column (hexane/EtOAc, 1:0 → 0:1), after which a fraction eluted by hexane/EtOAc (3:7) was further purified on a silica gel column with

CH₂Cl₂/hexane/EtOAc (5:3:2) to afford **1** (250 mg; 2.5% yield). The second fraction eluted by hexane/EtOAc (1:4) was further separated on a silica gel column with EtOAc/acetone/hexane (65:10:25). The first subfraction has been subjected to an ODS HPLC (80% MeOH(aq) with 0.1% formic acid, 3.0 mL/min, 254 nm) to give pure proceranolide (15 mg, 0.15%), and the second subfraction was subjected to an ODS HPLC (75% MeOH(aq) with 0.1% formic acid, 2.5 mL/min, 254 nm) to give **2** (25 mg, 0.25%) and 14-deoxyxylocensin K (19 mg, 0.19%). The third subfraction was subjected to the preparative TLC with EtOAc/acetone/hexane (65:10:25) to give **3** (16 mg, 0.16%).

Chisomicine A (1): white, amorphous powder; $[\alpha]_D^{27} -125$ (c 0.7, MeOH); IR (KBr) ν_{\max} 2938, 1734, and 1266 cm⁻¹; UV (MeOH) λ_{\max} (log ϵ) 202 (4.15), and 214 (sh, 4.02); CD (MeOH) λ_{\max} 201 ($\Delta\epsilon -36.2$), 213 (0), 227 (7.73), 290 (1.24) nm; ¹H NMR data (Table 1) and ¹³C NMR data (Table 2); ESIMS m/z 573 (M + Na)⁺; HRESIMS m/z 573.2464 (M + Na)⁺; calcd for C₃₂H₃₈O₈Na, 573.2464.

Chisomicine B (2): colorless needles; mp 176–178 °C; $[\alpha]_D^{27} -66$ (c 1.0, MeOH); IR (KBr) ν_{\max} 3391, 2972, 1735, 1703, and 1268 cm⁻¹; UV (MeOH) λ_{\max} (log ϵ) 216 (3.92); CD (MeOH) λ_{\max} 205 ($\Delta\epsilon$ 0), 209 (0.71), 213 (0), 223 (-3.42), 236 (0), 245 (0.92) nm; ¹H NMR data (Table 1) and ¹³C NMR data (Table 2); ESIMS m/z 591 (M + Na)⁺; HRESIMS m/z 569.2706 (M + H)⁺; calcd for C₃₂H₄₁O₉, 569.2751.

Chisomicine C (3): white, amorphous powder; $[\alpha]_D^{27} -86$ (c 1.0, MeOH); IR (KBr) ν_{\max} 3441, 2980, 1732, 1718, 1706, and 1269 cm⁻¹; UV (MeOH) λ_{\max} (log ϵ) 206 (4.16); CD (MeOH) λ_{\max} 201 ($\Delta\epsilon -4.86$), 208 (0), 211 (0.44), 217 (0), 221 (-0.3), 227 (0), 235 (0.48), 263 (0.93) nm; ¹H NMR data (Table 1) and ¹³C NMR data (Table 2); ESIMS m/z 607 (M + Na)⁺; HRESIMS m/z 607.2512 (M + Na)⁺; calcd for C₃₂H₄₀O₁₀Na, 607.2519.

X-ray Crystallography. Measurement was made on a Bruker SMART APEX CCD diffractometer with graphite-monochromated Mo K α radiation at -173 °C. Crystal data of chisomicine B: colorless platelet crystal, orthorhombic, C₃₂H₄₀O₉, $M = 568.64$, space group $P2_12_12_1$ (#9), $a = 12.4910(2)$ Å, $b = 13.4647(2)$ Å, $c = 34.3327(5)$ Å, $V = 5774.33$ Å³, $Z = 8$, $D_{\text{calc}} = 1.308$ g/cm³. Of the 55 933 reflections that




Figure 3. NO production ratio in J774.1 cells stimulated by LPS of chisomicine A (**1**). The assay was performed with $n = 3$.

Table 1. ¹H NMR Spectroscopic Data (J, Hz) of Chisomicines A–C (**1–3**) in CDCl₃^a

H	1	2	3
2	5.85 (1H, dd, 11.6, 6.4)	2.94 (1H, dd, 10.9, 3.4)	2.96 (1H, m)
3	4.79 (1H, dd, 6.4, 1.6)	4.80 (1H, d, 10.9)	4.80 (1H, d, 10.0)
5	3.82 (1H, brd, 12.0)	3.03 (1H, dd, 11, 2.3)	2.90 (1H, dd, 12.0, 10.0)
6a	2.52 (1H, dd, 16.0, 12.8)	2.33 (1H, dd, 17.2, 2.3)	2.37 (1H, d, 11.3)
6b	2.35 (1H, m)	2.27 (1H, m)	2.30 (1H, d, 11.3)
9	2.66 (1H, brd, 6.0)	1.80 (1H, m)	2.44 (1H, dd, 5.5, 4.6)
11a	1.87 (1H, brd, 14.4)	1.90 (1H, brd, 11.1)	1.66 (1H, bd, 14.0)
11b	1.63 (1H, m)	1.81 (1H, m)	1.51 (1H, m)
12a	1.30 (1H, m)	1.62 (1H, m)	1.25 (1H, m)
12b	1.04 (1H, m)	1.34 (1H, d, 11.1)	1.17 (1H, m)
14		2.04 (1H, dd, 6, 1.2)	
15a	3.07 (2H, brs)	2.50 (1H, dd, 18.4, 7.3)	2.94 (1H, d, 18.8)
15b		2.30 (1H, dd, 18.4, 1.8)	2.79 (1H, d, 18.8)
17	5.44 (1H, s)	5.40 (1H, s)	5.38 (1H, s)
18	1.09 (3H, s)	1.00 (3H, s)	1.01 (3H, s)
19	0.97 (3H, s)	1.00 (3H, s)	0.63 (3H, s)
21	7.54 (1H, brs)	7.70 (1H, brs)	7.78 (1H, brs)
22	6.46 (1H, brs)	6.40 (1H, brs)	6.46 (1H, brs)
23	7.39 (1H, brs)	7.40 (1H, brs)	7.39 (1H, brs)
28	1.13 (3H, s)	0.86 (3H, s)	1.01 (3H, s)
29a	2.40 (1H, d, 17.6)	2.00 (1H, d, 11)	3.93 (1H, d, 9.6)
29b	2.05 (1H, d, 17.6)	1.33 (1H, dd, 11, 1.5)	3.48 (1H, d, 9.6)
30	5.83 (1H, brd, 11.6)	3.25 (1H, d, 3.2)	5.48 (1H, d, 6.2)
OMe	3.72 (3H, s)	3.69 (3H, s)	3.69 (3H, s)
3'	7.29 (1H, qd, 7.0, 1.6)	6.97 (1H, qd, 9.0, 1.6)	6.92 (1H, d, 7.0)
4'	1.70 (3H, d, 7.0)	1.30 (3H, d, 9.0)	1.60 (3H, d, 7.0)
5'	1.76 (3H, brs)	1.80 (3H, brs)	1.77 (3H, brs)

^a δ in ppm.

Table 2. ^{13}C NMR Spectroscopic Data (δ) of Chisomicines A–C (1–3) in CDCl_3

C	1	2	3
1	220.6	80.0	97.3
2	135.5	43.9	45.2
3	76.8	78.6	75.3
4	43.3	44.8	43.3
5	40.5	39.4	34.8
6	33.8	34.2	31.8
7	174.1	173.8	173.9
8	131.0	61.3	140.9
9	44.4	41.6	43.8
10	54.2	45.1	41.4
11	19.1	21.5	19.1
12	28.5	33.7	28.6
13	37.8	36.0	41.2
14	131.6	44.8	72.9
15	33.0	27.3	39.3
16	169.2	169.4	169.3
17	80.2	77.6	76.9
18	16.4	22.0	14.9
19	22.9	18.8	14.7
20	120.7	120.8	120.0
21	141.7	141.4	142.1
22	109.9	109.7	109.9
23	142.8	143.1	143.1
28	22.6	15.0	15.5
29	46.4	43.3	67.9
30	129.1	59.6	121.8
OMe	52.0	52.0	52.2
1'	167.1	168.4	167.7
2'	127.9	128.0	127.4
3'	139.5	139.3	140.0
4'	14.3	14.2	14.7
5'	12.0	12.1	11.8

were obtained, 7315 were unique ($R_{\text{int}} = 0.0556$). The structure was solved by direct methods. $R_1 = 0.0479$ ($I > 2.00\sigma(I)$). All refinements were performed using SHELXL-97. The refined fractional atomic coordinates, bond lengths, bond angles, and thermal parameters have been deposited at the Cambridge Crystallographic Data Centre (CCDC). CCDC 805753 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge via <http://www.ccdc.cam.ac.uk/submit>, or from the CCDC, 12 Union Road, Cambridge CB2 1EZ, UK (fax: +44 1223 336 033; e-mail: deposit@ccdc.cam.ac.uk).

NO Production Assay by J774.1 Cells. The J774.1 cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum and penicillin/streptomycin. Cells were seeded onto a 96-well microtiter plate at 1×10^5 cells in $100 \mu\text{L}$ of solution per well and were preincubated for 12 h at 37°C in a humidified atmosphere containing 5% CO_2 . The cells were cultured in the medium containing LPS ($5 \mu\text{g}/\text{mL}$) with or without the test sample at different concentrations for 24 h. NO production was then determined by the Griess assay. Supernatant of the cultured medium ($100 \mu\text{L}$) was transferred to a 96-well microtiter plate, and then $100 \mu\text{L}$ of Griess reagent (1% sulfanilamide, 0.1% *N*-1-naphthylethylenediamine dihydrochloride in 2.5% H_3PO_4) was added. After incubation at room temperature for 15 min, the absorbance at 540 and 620 nm was measured

with a microplate reader (Benchmark Plus microplate spectrometer, Bio-Rad). L-NMMA, an NO synthase inhibitor, was used as a positive control (IC_{50} $13.8 \mu\text{g}/\text{mL}$).

Cell Viability Assay. The cell viability was determined by MTT assay. MTT ($15 \mu\text{L}$ of a $5 \text{ mg}/\text{mL}$ solution) was added into each well of the cultured medium. After a 2 h incubation period, the medium was removed, and then $50 \mu\text{L}$ of DMSO was added to resolve the formazan crystals. Optical density measurements were made using a microplate reader equipped with a two-wavelength system at 550 and 700 nm. In each experiment, three replicates were prepared for each sample. The ratio of living cells was determined on the basis of the difference of the absorbance between those of samples and controls.

ASSOCIATED CONTENT

Supporting Information. Selected 2D NMR correlations, plausible biogenetic path, ^1H and ^{13}C NMR spectra, 2D NMR correlations of 1–3, and atom coordinate of 1 are available free of charge via the Internet at <http://pubs.acs.org>.

AUTHOR INFORMATION

Corresponding Author

*Tel: 603-79674010. Fax: 603-79674193. E-mail: ahamid@um.edu.my. Tel: (03)5498-5778. Fax: (03)5498-5778. E-mail: moritah@hoshi.ac.jp.

ACKNOWLEDGMENT

This work was partly supported by University Malaya Research grants PS378/2009B, a CNRS (France) grant, a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan, and a grant from the Open Research Center Project.

REFERENCES

- (1) (a) Taylor, D. A. H. In *Progress in the Chemistry of Organic Natural Products*; Herz, W., Grisebach, H., Kirby, G. W., Eds.; Springer: New York, 1984; Vol. 45. (b) Mulholland, D. A.; Parel, B.; Coombes, P. H. *Curr. Org. Chem.* **2000**, *4*, 1011–1054.
- (2) (a) Zhang, H.; Wang, X.; Chen, F.; Androurakis, X. M.; Wargovich, M. J. *Phytother. Res.* **2007**, *21*, 731–734. (b) Roy, A.; Saraf, S. *Biol. Pharm. Bull.* **2006**, *29*, 191–201. (c) Carpinella, M. C.; Defago, M. T.; Valladares, G.; Palacios, S. M. *J. Agric. Food Chem.* **2003**, *51*, 369–374. (d) Bray, D. H.; Warhurst, D. C.; Connolly, J. D.; O'Neill, M. J.; Phillipson, J. D. *Phytother. Res.* **1990**, *4*, 29–35.
- (3) (a) Yin, S.; Wang, X. N.; Fan, C. Q.; Liao, S. G.; Yue, J. M. *Org. Lett.* **2007**, *9*, 2353–2356. (b) Zhang, C. R.; Yang, S. P.; Liao, S. G.; Fan, C. Q.; Wu, Y.; Yue, J. M. *Org. Lett.* **2007**, *9*, 3383–3386. (c) Di, Y. T.; He, H. P.; Liu, H. Y.; Yi, P.; Zhang, Z.; Ren, Y. L.; Wang, J. S.; Sun, Q. Y.; Yang, F. M.; Fang, X.; Li, S. L.; Zhu, H. J.; Hao, X. J. *J. Nat. Prod.* **2007**, *70*, 1352–1355.
- (4) (a) Mohamad, K.; Hirasawa, Y.; Lim, C. S.; Awang, K.; Hadi, A. H. A.; Takeya, K.; Morita, H. *Tetrahedron Lett.* **2008**, *49*, 4276–4278. (b) Mohamad, K.; Hirasawa, Y.; Litaudon, M.; Awang, K.; Hadi, A. H. A.; Takeya, K.; Ekasari, W.; Widyawaruyanti, A.; Zaini, N. C.; Morita, H. *Bioorg. Med. Chem.* **2009**, *17*, 727–730. (c) Piow, W. C.; Shimada, M.; Nagakura, Y.; Nugruho, A. E.; Hirasawa, Y.; Kaneda, T.; Awang, K.; Hadi, A. H. A.; Mohamad, K.; Shiro, M.; Morita, H. *Chem. Pharm. Bull.* **2011**, *59*, 407–411.
- (5) (a) Awang, K.; Lim, C. S.; Mohamad, K.; Morita, H.; Hirasawa, Y.; Takeya, K.; Thoison, O.; Hadi, A. H. A. *Bioorg. Med. Chem.* **2007**, *15*, 5997–6002. (b) Najmuldeen, I. A.; Hadi, A. H. A.; Mohamad, M.; Awang, K.; Ng, S. W. *Acta Crystallogr.* **2010**, *E66*, o1927.

- (6) Kim, J.-G.; Cho, D. H.; Jang, D. O. *Tetrahedron Lett.* **2004**, *45*, 3031–3033.
- (7) Sondengam, B. L.; Kamga, C. S.; Connolly, J. D. *Phytochemistry* **1980**, *19*, 2488–2488.
- (8) Yin, S.; Wang, X.-N.; Fang, C.-Q.; Li, P.-L.; Ding, J.; Yue, J.-M. *J. Nat. Prod.* **2007**, *70*, 682–685.
- (9) *TURBOMOLE V6.1 2009*, a development of University of Karlsruhe and Forschungszentrum Karlsruhe GmbH, 1989–2007, TURBOMOLE GmbH, since 2007; available from <http://www.turbomole.com>.
- (10) (a) Eickorn, K.; Treutler, O.; Ohm, H.; Haser, M.; Ahlrichs, R. *Chem. Phys. Lett.* **1995**, *240*, 283–289. (b) Becke, A. D. *Phys. Rev. A* **1988**, *38*, 3098–3100. (c) Perdew, J. P. *Phys. Rev. B* **1986**, *33*, 8822–8824. (d) Schafer, A.; Horn, H.; Ahlrichs, R. *J. Chem. Phys.* **1992**, *97*, 2571–2577. (e) Weigend, F.; Kohn, A.; Hattig, C. *J. Chem. Phys.* **2002**, *116*, 3175–3183.
- (11) Aktan, F. *Life Sci.* **2004**, *75*, 639–653.